Call for Postmarketing CV Studies
Panel’s Hot Air Ends in Yes for Theravance/GSK COPD Bid
By Randy Osborne
Tuesday, September 10, 2013
Panelists on the FDA’s Pulmonary-Allergy Drugs Advisory Committee that convened to decide about Anoro Ellipta, the inhaler product for chronic obstructive pulmonary disease (COPD), proved harder to satisfy than briefing documents might have led Glaxosmithkline plc (GSK) and partner Theravance Inc. to expect.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.